DRUG COSTS AND PATIENTACCESS: BIOLOGICS VS. SMALL MOLECULES | International Journal of Drug Research and Technology
Reach Us +447456396942
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal

Editorial - (2021) Volume 10, Issue 9


Wen Li*
*Correspondence: Wen Li, Department of Pharmacy, New Bulgarian University, Bulgaria, Email:
Department of Pharmacy, New Bulgarian University, Bulgaria

Received: 17-Sep-2021 Published: 05-Oct-2021


Huge advancements in drug research are thus investigated first to lay the groundwork for a fundamental understanding of the financial viability of biologics and small particles, why biologic medications are more expensive, and what medication cost typically means for patient admission to one medication class over the other. Also emphasised is the need for the pharmaceutical industry, particularly the biopharmaceutical industry, to consider a reassignment of needs so that more patients can benefit from the extraordinary benefits that come with blockbuster drugs, many of which are of organic origin but incredibly expensive.

To avoid the catastrophic impact of high pharmaceutical costs on the powerless majority of patients – those who can't afford them – a balance between the adequacy of miracle-working drugs and the patient's financial ability to get them should be established. The overarching point that has been emphasised is that genuine achievement in drug discovery and improvement, as well as in the delivery of medical services, should be measured by the magnitude of logical leaps forwards as well as the extent to which they are affordable to patients as determined by their costs. To improve patients' access to innovative and improved medical treatments and medicines.

More investigation should be given to less expensive options such as small particle generics, biosimilars, and neutralizer drug forms; government arrangements should be put in place to facilitate the commercialization of biosimilars; and drug companies should be generous enough to run assistance programmes for qualified financially handicapped patients while attempting to profit from the market.

o Biologics are less accessible to patients than small molecules.

o Governments can help to enhance patient access to drugs by policy changes.

o More assistance foundations are needed to reach more patients with drugs.

o Drug accessibility is as important as drug efficacy and profit-making.

o Small molecules are more economically sustainable than biologics.